Objective-BubR1, a cell cycle-related protein, is an essential component of the spindle checkpoint that regulates cell division.
A rteries respond to damaging stimuli, such as injury, inflammation, and stretch, by activating a remodeling mechanism that leads to neointimal hyperplasia. 1, 2 Accumulating evidence has shown that the underlying causes of neointimal hyperplasia include the invasion and proliferation of vascular smooth muscle cells (VSMCs), via processes triggered and controlled by various growth factors. 2 Excessive proliferation and migration of VSMCs from the arterial media to the neointima are the major causes of neointimal hyperplasia. 2 Furthermore, leukocyte and macrophage infiltration to the neointima are key components of atherosclerosis. 2 These contribute to the development and progression of vascular disorders, including atherosclerosis and restenosis after angioplasty for coronary artery disease or endovascular treatment of peripheral arterial disease. [3] [4] [5] The spindle assembly checkpoint is a surveillance mechanism that prevents chromosome missegregation during the division of eukaryotic cells by delaying the metaphase-toanaphase transition until all chromosomes become properly attached to the spindle microtubules and align at the metaphase plate. Core components of the spindle assembly checkpoint include the evolutionarily conserved proteins Bub1, Bub3, Mad1, Mad2, BubR1 (Mad3 in yeast), Mps1, and Aurora B. [6] [7] [8] [9] The cell cycle-related protein BubR1 is an essential component of the spindle assembly checkpoint and has important roles in cell division. Previous studies 10, 11 revealed that mice with BubR1 expression reduced to 10% of the normal level, termed BubR1 hypomorphic mice, develop progressive aneuploidy, cataracts, lordokyphosis, loss of subcutaneous fat, impaired wound healing, severely shortened lifespan, and infertility, together with early aging-associated vascular phenotypes, including a reduced number of smooth muscle cells, reduced elasticity, impaired endothelial-dependent relaxation, and increased production of superoxide anions. However, it is difficult to evaluate smooth muscle proliferation in vivo because the initial number of smooth muscle cells in these mice is low. 11 Therefore, we newly generated mice in which BubR1 expression was reduced February 2015 to 20% of the normal level. These mice do not display significant abnormalities, such as progeria, infertility, shortened lifespan, and abnormal vascular structures during growth and development under normal conditions. These mice, with a low BubR-expressing mutant genotype (termed BubR1 L/L mice), are particularly suitable for investigating the precise roles of BubR1 in the vasculature. Here, we describe the effects of low BubR1 expression on arterial neointimal hyperplasia in mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of BubR1 L/L Mice
Targeted insertion of the neo gene into an intron of an endogenous mouse gene, with reverse orientation, produced a mutant allele that generated pre-mRNA harboring a cryptic neo exon ( Figure 1A ). During pre-RNA splicing, this exon was either spliced into the mRNA product or spliced out. The mRNAs carrying the cryptic exon were translated into truncated proteins because neo sequences introduce stop codons in all 3 reading frames. Consequently, the small amount of normal mRNA generated from the mutant allele was translated into wild-type proteins. Tail DNA from BubR1 +/+ , BubR1 +/L , and BubR1 L/L mice was subjected to polymerase chain reaction (PCR) genotyping using 3 primers that anneal to the neo gene and the upper and lower sides of the neo gene. Wild-type (BubR1 +/+ ) DNA was amplified by primers targeting the intron, which yielded a 475-bp fragment ( Figure 1B ). By contrast, DNA from BubR1 L/L mice was amplified by primers targeting the intron and the neo gene, which yielded a 938-bp fragment. DNA from heterozygous mice (BubR1 +/L ) was amplified by primers targeting the intron and neo gene, yielding 475-and 938-bp fragments.
Next, we performed quantitative real-time PCR to determine the relative expression of BubR1 in the thymus and confirmed that its expression in BubR1 L/L mice was 20.9% of that in BubR1 +/+ mice ( Figure 1C ). BubR1 L/L mice had a normal appearance and size at birth but showed slow postnatal growth ( Figure 1D ).
Effects of Low BubR1 Expression on Neointimal Hyperplasia After Carotid Ligation
In response to an interruption of carotid blood flow, neointimal hyperplasia occurs via the proliferation and migration of VSMCs from the medial layer of the artery. Before carotid ligation, there was no difference in common carotid arterial size (vascular area), containing cell numbers and cell density in the vascular area of mice with either genotype ( Figure IA in the online-only Data Supplement). Furthermore, no intimal thickening was present in either genotype ( Figure IB in the online-only Data Supplement). There was no statistically significant difference between the body weight of male BubR1 +/+ and BubR1 L/L mice at the age of 10 weeks ( Figure 1D ), as well as female mice ( Figure IC in the online-only Data Supplement). In addition, the lifespan of male and female BubR1 +/+ and BubR1 L/L mice was similar (data not shown). No progeroid phenotype appeared in either male ( Figure 1D ) or female BubR1 L/L mice ( Figure IC in the online-only Data Supplement). In arterial tissues, such as the aorta and carotid artery, we evaluated that the expression level of BubR1 derived from BubR1 L/L mice was reduced to 18.1% (aorta) and 20.0% (common carotid artery) compared with that of BubR1 +/+ mice. In other organs, such as the heart, liver, spleen, kidney, testis, and small intestine, BubR1 expression levels in male BubR1 L/L mice were reduced to 18.3, 29.9, 38.0, 20.6, 73.6, and 20.3%, respectively, compared with those in BubR1 +/+ mice, and organ weights were comparable except for the spleen. The weight of the spleen in BubR1 L/L mice was superior to that of BubR1 +/+ mice (data not shown). In this study, we used 10-weekold male mice for analysis of the carotid ligation model.
We evaluated the time-dependent change of BubR1 expression in ligated common carotid arteries. Expression levels of BubR1 in the ligated arteries derived from BubR1 L/L mice were reduced to 21.1% (preoperative), 50.7% (3 days), 64.2% (1 week), 36.8% (2 weeks), and 15.7% (4 weeks) compared with that of BubR1 +/+ mice, which were significantly lower preoperatively, 2 and 4 weeks after ligation (Figure 2A ). BubR1 expression 3 days after ligation was significantly higher preoperatively in both genotypes (Figure 2A ).
Next, we evaluated the ligated arteries using morphological analysis. Significant neointimal hyperplasia was found 4 weeks after carotid ligation in BubR1 +/+ mice, whereas neointimal hyperplasia was almost completely inhibited in BubR1 L/L mice ( Figure 2B , top). Quantitative morphometry confirmed that the intimal area (4180±314 versus 23 561±4107 μm 2 ; P<0.01) and intima:media ratio (0.12±0.01 versus 0.68±0.10; P<0.01) were significantly lower in BubR1 L/L mice than those in BubR1 +/+ mice ( Figure 2B, bottom) . These results indicate that reduced BubR1 expression is associated with a decrease of intimal thickening caused by carotid ligation. Some previous studies have revealed that vascular smooth muscle progenitor cells derived from bone marrow are involved in the neointimal hyperplasia induced by vascular injury. 3, 12 So, we next investigated the effects of bone marrow transplantation on neointimal hyperplasia.
Within the same cell, BubR1 L/L mice had both wild-type BubR1 mRNA and low-expressed BubR1 mRNA ( Figure 1A) , which made it difficult to evaluate the bone marrow replacement rate by flow cytometric analysis. We, therefore, evaluated the bone marrow replacement rate using C57BL/6 (recipient) and green fluorescent protein (donor) mice in an identical manner, which revealed that the recipient mice had 91.7% of total blood cells derived from the donor mice (n=5). Bone marrow transplantation from all donors did not affect reconstitution of the 3 hematopoietic lineages ( Table I in Figure 2C) . These results suggest that the vascular smooth muscle progenitor cells from bone marrow did not contribute to neointimal hyperplasia observed in this study.
Migration and Proliferative Capacity Evaluated in Cultured VSMCs From BubR1 L/L Mice
Because neointimal hyperplasia after carotid artery ligation involves migration and proliferation of VSMCs from the medial layer of the artery ( Figure IIA in the online-only Data Supplement) after infiltration of macrophages into the media ( Figure IIB in the online-only Data Supplement), we determined the migration and proliferative capacity of primary cultured VSMCs. VSMCs were isolated by enzymatic dispersion as previously described. 13 VSMCs from BubR1 +/+ and BubR1 L/L mice were positive for smooth muscle cell markers, including α-smooth muscle actin, smooth muscle 22-α, and smooth muscle myosin heavy chain ( Figure 3A ). Using quantitative real-time PCR, we confirmed that BubR1 mRNA expression in BubR1 L/L VSMCs was reduced to 25.8% of that in BubR1 +/+ VSMCs ( Figure 3B ).
First, we determined whether reduction of BubR1 affected the migration of VSMCs using transwell migration assays. However, exposure to serum and platelet-derived growth factor (PDGF)-BB increased the number of migrated VSMCs, and the number of migrated cells was not significantly different between BubR1 +/+ and BubR1 L/L VSMCs ( Figure 3C ).
Next, we compared the proliferative capacities of BubR1 +/+ and BubR1 L/L VSMCs by comparing growth curves. The proliferation of BubR1 L/L cells was significantly slower than that of BubR1 +/+ cells in the presence of fetal bovine serum with or without 10 ng/mL PDGF-BB at 3, 5, and 7 days after plating ( Figure 3D ). Immunohistochemical analysis of the ligated carotid arteries, to determine the proliferation capacity, was performed using Ki67immunohistochemical staining. We found that medial VSMC proliferation was significantly reduced in BubR1 L/L mice compared with that in BubR1 +/+ mice ( Figure IIC Figure 3 shows the low proliferative rate of VSMCs isolated from BubR1 L/L mice. To determine whether BubR1 regulates the cell cycle of VSMCs, we performed cell cycle analysis of PDGF-BB-stimulated VSMCs by measuring the DNA content of cells stained with propidium iodide ( Figure 4A ). There were no significant differences between BubR1 +/+ and BubR1 L/L VSMCs in terms of proportions of cells in the G0/ G1 and G2/M phases ≤24 hours or in the S phase ≤12 hours. However, BubR1 L/L VSMCs showed delayed entry into the S phase at 18 hours after serum and PDGF-BB stimulation ( Figure 4B) . These results suggest that low BubR1 expression delays cell cycle progression through the S phase and suppresses PDGF-BB-stimulated VSMC proliferation.
Effects of Low BubR1 Expression on PDGF-BB-Stimulated Cell Cycle Progression
Effects of Low BubR1 Expression on p38 Expression in VSMCs
A previous report has shown that a p38 mitogen-activated protein kinase inhibitor, SB203580, inhibits angiotensin II-induced BubR1 expression in human aortic smooth muscle cells. 14 To determine whether BubR1 regulates the expression level of p38 in VSMCs, we performed quantitative real-time PCR to determine the relative expression of p38 in the VSMCs and confirmed that its expression in BubR1 L/L mice was 44.7% of that in BubR1 +/+ mice ( Figure 5A ). Next, we evaluated the effect of SB203580 on BubR1 expression. The BubR1 expression of SB203580mediated VSMCs derived from BubR1 +/+ mice was reduced to 37.1% of that in control VSMCs by p38 inhibition (Figure 5B ). BubR1 knockdown was confirmed by quantitative real-time PCR, which revealed that its expression in siRNA-mediated knockdown VSMCs was 31.6% of that in scrambled control siRNA-mediated VSMCs (data not shown). siRNA-mediated knockdown of BubR1 had an inhibitory influence on the expression of p38 ( Figure 5C ). Taken together, these data indicate that BubR1 and p38 mutually affect each other, which has an influence on the impaired proliferation of VSMCs in BubR1 L/L mice.
Discussion
Several lines of evidence suggest that low BubR1 expression is implicated in various disorders, especially progeroid-and aging-associated phenotypes, such as short lifespan, dwarfism, facial dysmorphism, cataract, sarcopenia, infertility, subdermal fat loss, impaired wound healing, and reduced dermal thickness. 10 In terms of vascular effects, it is previously reported that BubR1 hypomorphic mice display the following phenotypes: reduced arterial wall thickness, narrower inner diameter, low numbers of medial VSMCs, profound arterial wall fibrosis, reduced artery elasticity, reduced endothelium-dependent and endothelium-independent relaxation in response to nitric oxide, and reduced arterial compliance. 11 Nevertheless, the precise role of BubR1 in vascular disorders is unknown. Until now, no reports have described the role of BubR1 in vascular remodeling or the involvement of migration or proliferation of VSMCs in this process. In the present study, we determined the role of the cell cycle-related protein BubR1 in the vascular response to blood flow cessation in BubR1 L/L mice generated in our laboratory. We found that reduced BubR1 expression inhibited intimal hyperplasia after carotid artery ligation in a process that involved reduced proliferation of VSMCs through delayed cell cycle progression and impaired PDGF-BB-stimulated proliferation, without changes in VSMC migration.
BubR1 hypomorphic mice showed early aging-associated vascular disorders, including a reduced number of smooth muscle cells, reduced elasticity, impaired endothelial-dependent relaxation, and increased superoxide anion production. 11 However, it was difficult to evaluate smooth muscle proliferation capacity in vivo because the number of smooth muscle cells in the vascular media was initially low in the BubR1 hypomorphic mice. 11 Therefore, we generated mice with BubR1 expression that was ≈20% of that in BubR1 +/+ mice, without major abnormalities, such as progeria, infertility, and shortened lifespan during development and growth, allowing us to investigate the role of BubR1 in vascular biology. Because the number of smooth muscle cells in the carotid artery media was not significantly different between BubR1 +/+ and BubR1 L/L mice, we investigated the effects of low BubR1 expression on arterial neointimal hyperplasia.
Many studies have examined the responses of the arterial wall to a variety of stressors, including injury or blood flow cessation, and many growth factors have been implicated in neointimal hyperplasia. The proliferation and migration of VSMCs are thought to be essential components of neointimal hyperplasia in atherosclerosis and after mechanical arterial injury, for example, after angioplasty. 15 PDGF plays a primary role in inducing VSMC proliferation and migration in vivo. 15 In the present study, intimal hyperplasia was almost completely inhibited in BubR1 L/L mice after carotid artery ligation ( Figure 2B) . The analysis for time-dependent change of BubR1 expression in ligated common carotid arteries showed that BubR1 expression was transiently elevated after ligation in both genotypes, which suggested that induction of BubR1 might contribute to neointimal hyperplasia (Figure 2A ).
Studies report that bone marrow-derived vascular smooth muscle progenitor cells are mobilized into the circulation from the bone marrow, whereby they home to sites of injury and differentiate into vascular smooth muscle-like cells, thereby contributing to neointimal hyperplasia. 3, 12 In the present study, bone marrow transplantation did not affect neointimal hyperplasia after carotid ligation, which indicates that the recipient phenotype was the primary determinant of the degree of neointimal hyperplasia. In BubR1 L/L mice, the growth of splenic T cells, in which BubR1 expression was reduced to ≈40% of that in BubR1 +/+ mice, was not significantly different from that of T cells from BubR1 +/+ mice (data not shown). The reduced influence on hematopoietic lineages may be because of the higher expression level in T cells (40% in T cells versus 20% in VSMCs). BubR1 plays an important role in cell cycle progression by means of a threshold mechanism.
VSMCs within the medial layer of arteries are normally in a quiescent state. However, in response to vascular stress, such as angioplasty, a subpopulation of medial VSMCs migrate to the neointima where they proliferate, ultimately resulting in neointimal hyperplasia. 16 Growth factors, such as PDGF, that aggregate at the site of injury, are thought to be involved in this process. 17 Therefore, we examined the role of BubR1 in PDGF-BB-stimulated cellular activities in VSMCs in vitro. However, we found that PDGF-BB-induced migration of VSMCs was not defective in BubR1 L/L mice ( Figure 3C) , and PDGF-BB-stimulated VSMC proliferation was significantly reduced in BubR1 L/L VSMCs ( Figure 3D ), which was consistent with our in vivo findings ( Figure 2B ). Thus, low BubR1 expression is responsible for a slower growth of VSMCs but does not significantly affect VSMC migration.
Cell proliferation is tightly controlled by a series of regulators that act at sequential points throughout the cell cycle. The G1→S phase transition is controlled by cyclin-dependent kinase complexes and is promoted by phosphorylation of the retinoblastoma protein. 18 Ligand-induced activation of peroxisome proliferator-activated receptor-α prevents the G1→S phase transition and proliferation of VSMCs by increasing the transcription of the cyclin-dependent kinase inhibitor p16. 19 Tissues in BubR1 hypomorphic mice, including skeletal muscle, adipose, and eye, are reported to have much higher levels of p16 compared with those in BubR1 +/+ mice, but there are no significant differences in p16 expression levels in other tissues, including the aorta. 20 Similar to this previous report, we found no significant difference in p16 mRNA expression between VSMCs derived from our BubR1 L/L mice and BubR1 +/+ mice (data not shown). So, it seems that other mechanisms are concerned in the delayed VSMC proliferation of BubR1 L/L mice.
We previously reported that the p38 mitogen-activated protein kinase inhibitor, SB203580, inhibits angiotensin II-induced BubR1 expression in human aortic smooth muscle cells. 14 These findings support the hypothesis that p38 mitogen-activated protein kinase is an upstream mediator of BubR1 activation in VSMCs. In this study, we found that reduced BubR1 expression also has an inhibitory influence on p38 expression in VSMCs ( Figure 5A ). Furthermore, siRNA-mediated BubR1 knockdown repressed p38 expression ( Figure 5C ). This result indicates that impaired BubR1 expression is associated with decreased expression of p38. We also evaluated the influence of p38 inhibition on VSMCs. Exposure to SB203580 resulted in lower expression of BubR1 in VSMCs derived from BubR1 +/+ mice. Taken together, BubR1 and p38 mutually affected each other, which may be one of the reasons for the impaired proliferation of VSMCs in BubR1 L/L mice compared with BubR1 +/+ mice. In another report, the interleukin-8 receptor B antagonist, SB225002, is shown to induce the phosphorylation of BubR1 in a dose-dependent manner. 21 These data further support the interaction between BubR1 and p38. p38 may therefore represent an alternative potential target for antiatherosclerosis treatment aside from BubR1.
Conclusions
We generated BubR1 L/L mice in which BubR1 expression was ≈20% of that in BubR1 +/+ mice. The BubR1 L/L mice did not display significant abnormalities of the vascular structures, including progeria, infertility, or shortened lifespan during growth and development. We, therefore, used these mice to examine the role of BubR1 in vascular biology. Low BubR1 expression almost completely inhibited intimal hyperplasia after carotid ligation by suppressing the proliferation of VSMCs, which was caused, in part, by delayed cell cycle progression. VSMCs derived from BubR1 L/L mice might impair the proliferative capacity through the inhibition of p38 expression. These findings suggest that BubR1 may represent a potential target molecule for treating pathological vascular remodeling, including restenosis after angioplasty.
